ACceptability of long-acting ART in Cognitive ImpAirment (ACACIA)
- Conditions
- People living with HIV who have a cognitive impairmentMental and Behavioural Disorders
- Registration Number
- ISRCTN14933807
- Lead Sponsor
- niversity of Sussex
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 20
1. Eligible for LA injectable ART by the multidisciplinary (MDT) clinical team at University Hospitals Sussex NHS Foundation Trust based on criteria defined by the British HIV Association (BHIVA)
2. HIV-1 positive subjects
3. Age = 40 years old
4. Evidence of clinically significant cognitive impairment, which for this protocol will be defined as participants meeting all of the following criteria:
4.1. Patient-reported symptoms of cognitive impairment (ongoing symptoms)
4.2. Current or past clinical neuropsychological testing reporting cognitive impairment
5. Able to understand the study, sign the consent form, and be willing to undertake all study procedures
1. Patient deemed not to be eligible for LA injectable CAB+RPV by the MDT clinical team and based on the criteria defined by BHIVA
2. Existing neurological disease that could affect the ability of patients to participate in the study
3. Current history of major depression or psychosis
4. Recent head injury (past six months)
5. Current alcohol abuse or drug dependence
6. Has completed the CogniFit assessment in the last year for clinical or research purposes
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Health-related quality of life is measured using patient reported outcome measures (DEMQOL, WHOQOL and HIVPROM) at baseline (day 0), week 4 (following oral CAB+RPV lead-in) and at week 48 (study end)
- Secondary Outcome Measures
Name Time Method